SCHEMBL3205673

SCHEMBL3205673

CC(=N)Nc1ccc2nc(-c3ccccc3F)ncc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.43
MEN1 O00255 7/20 0.43
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 3/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 1/20 0.43
FGFR4 P22455 1/20 0.41
ADORA3 P0DMS8 2/20 0.41
ADORA2A P29274 2/20 0.41
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
NPC1 O15118 5/20 0.37
MAOA P21397 2/20 0.36
MAOB P27338 2/20 0.36
ADORA1 P30542 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RAB9A P51151 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3182261 0.86 MAOA (0.52) SMN1; SMN2KDM4EALDH1A1FGFR4ADORA3
SCHEMBL3202990 0.85 MAPT (0.41) KMT2AMEN1MAPTKDM4EFGFR4
SCHEMBL3191800 0.83 MAOA (0.50) KMT2AMEN1MAPTSMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL3204239 0.82 MAOA (0.49) KMT2AMEN1MAPTSMN1; SMN2KDM4E
SCHEMBL3202582 0.81 ADORA2A (0.43) KMT2AMEN1MAPTSMN1; SMN2KDM4E
SCHEMBL3196775 0.81 MEN1 (0.40) KMT2AMEN1MAPTALDH1A1FGFR4
SCHEMBL3183539 0.80 NPC1 (0.44) KMT2AMEN1MAPTSMN1; SMN2KDM4E
SCHEMBL3201640 0.76 FGFR4 (0.41) KMT2AMEN1MAPTSMN1; SMN2KDM4E
SCHEMBL3195581 0.76 LCK (0.43) ADORA3
SCHEMBL3194081 0.75 MET (0.41) KMT2AMEN1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120802-A1 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production MAKOVEC FRANCESCO 2010-05-13 US disclosed
US-7674809-B2 Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM S.P.A. (IT) 2010-03-09 US disclosed
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production ROTTAPHARM SPA 2005-09-08 US disclosed
EP-1571142-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production Rottapharm S.p.A. (IT) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120802-A1 Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production NOS3, NOS1, NOS2 KMT2A 3630/4885MEN1 3366/4885MAPT 4542/4885
US-20050197331-A1 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production NOS3, NOS1, NOS2 KMT2A 3630/4885MEN1 3366/4885MAPT 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.